BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,775,000 | -27.0% | 4,100 | -12.8% | 0.14% | -23.9% |
| Q4 2021 | $2,431,000 | -3.5% | 4,700 | -9.6% | 0.18% | -5.6% |
| Q3 2021 | $2,520,000 | -6.7% | 5,200 | -13.3% | 0.20% | -4.9% |
| Q2 2021 | $2,702,000 | +16.0% | 6,000 | -1.6% | 0.20% | +12.6% |
| Q1 2021 | $2,330,000 | +3.3% | 6,100 | -14.1% | 0.18% | +12.3% |
| Q4 2020 | $2,255,000 | +9.7% | 7,100 | -14.5% | 0.16% | -9.0% |
| Q3 2020 | $2,056,000 | -10.5% | 8,300 | -4.6% | 0.18% | -9.2% |
| Q2 2020 | $2,297,000 | +1.0% | 8,700 | -27.5% | 0.20% | -15.5% |
| Q1 2020 | $2,275,000 | +15.1% | 12,000 | +33.3% | 0.23% | +68.1% |
| Q4 2019 | $1,976,000 | +6.3% | 9,000 | -5.3% | 0.14% | +2.2% |
| Q3 2019 | $1,859,000 | +20.5% | 9,500 | +28.4% | 0.14% | +23.9% |
| Q2 2019 | $1,543,000 | +3.6% | 7,400 | -1.3% | 0.11% | +0.9% |
| Q1 2019 | $1,489,000 | +42.9% | 7,500 | +4.2% | 0.11% | +13.7% |
| Q4 2018 | $1,042,000 | -33.7% | 7,200 | -6.5% | 0.10% | -20.2% |
| Q3 2018 | $1,572,000 | +1.2% | 7,700 | -26.7% | 0.12% | -2.5% |
| Q2 2018 | $1,553,000 | -21.5% | 10,500 | -19.8% | 0.12% | -26.1% |
| Q1 2018 | $1,979,000 | +9.9% | 13,100 | -5.8% | 0.16% | +5.1% |
| Q4 2017 | $1,801,000 | -45.6% | 13,900 | -49.3% | 0.16% | +10.6% |
| Q3 2017 | $3,312,000 | +63.9% | 27,400 | +59.3% | 0.14% | -20.2% |
| Q2 2017 | $2,021,000 | +13.6% | 17,200 | -1.7% | 0.18% | +2.3% |
| Q1 2017 | $1,779,000 | -18.4% | 17,500 | -17.5% | 0.17% | -32.0% |
| Q4 2016 | $2,180,000 | -13.4% | 21,200 | -7.8% | 0.26% | -22.0% |
| Q3 2016 | $2,518,000 | -5.0% | 23,000 | -2.1% | 0.33% | -15.0% |
| Q2 2016 | $2,650,000 | +12.1% | 23,500 | -6.0% | 0.39% | +3.5% |
| Q1 2016 | $2,363,000 | -4.2% | 25,000 | -8.8% | 0.37% | -8.6% |
| Q4 2015 | $2,466,000 | -17.7% | 27,400 | -15.4% | 0.41% | -18.2% |
| Q3 2015 | $2,996,000 | +11.2% | 32,400 | +18.4% | 0.50% | +19.1% |
| Q2 2015 | $2,694,000 | -1.8% | 27,360 | 0.0% | 0.42% | -2.6% |
| Q1 2015 | $2,744,000 | +8.5% | 27,360 | 0.0% | 0.43% | +0.2% |
| Q4 2014 | $2,528,000 | – | 27,360 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |